Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139412 | 1.00 | BACE1 (0.57) | BACE1FGFR1NPC1RAB9AALDH1A1 | |
| SCHEMBL4152977 | 0.89 | BACE1 (0.64) | BACE1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4152976 | 0.89 | BACE1 (0.64) | BACE1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4150692 | 0.86 | BACE1 (0.57) | BACE1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4150691 | 0.86 | BACE1 (0.57) | BACE1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL4136351 | 0.82 | BACE1 (0.61) | BACE1 | |
| SCHEMBL4136356 | 0.82 | BACE1 (0.61) | BACE1 | |
| SCHEMBL4155652 | 0.81 | BACE1 (0.57) | BACE1ALDH1A1MAPT | |
| SCHEMBL4155646 | 0.81 | BACE1 (0.57) | BACE1ALDH1A1MAPT | |
| SCHEMBL5332042 | 0.81 | BACE1 (0.61) | BACE1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | ASTEX THERAPEUTICS (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221579-A1 | Substituted Amino-Compounds and Uses Thereof | APP, PSEN1, BACE1 | BACE1 3/4885FGFR1 3806/4885NPC1 1190/4885 |
| US-20090062282-A1 | Substituted Amino-Pyrimidones and Uses Thereof | APP, PSEN1, PSEN2 | BACE1 4/4885FGFR1 2364/4885NPC1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.